Sign inJoin waitlistJoin the waitlist

Stephanie Graff

Director of Breast Oncology · Alpert Medical School

Credentials: · · · · · · ·

History

Alpert Medical School
Present

Hematology and Medical Oncology
University of Kansas
2007–2010
Internal Medicine
University of Missouri-Kansas City School of Medicine
2004–2007
University of Kansas School of Medicine
2000–2004

Research

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update
Journal of Clinical Oncology · 2018 · 114 citations
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update
Journal of Clinical Oncology · 2021 · 92 citations
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
Journal of Clinical Oncology · 2025 · 91 citations

George Sledge
8 papers
Don Dizon
7 papers
Liang Cheng
7 papers
Wafik El-Deiry
7 papers
Yihong Wang
7 papers
EH
Erika Hamilton
5 papers
Julia Close
5 papers
Merry-Jennifer Markham
5 papers
Elizabeth Dibble
4 papers
GU
Gary Ulaner
4 papers
Heather Jacene
4 papers
IS
Ishwaria Subbiah
4 papers

Clinical trials

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
Principal investigator · Recruiting · Phase 2
Brown University
2025–2029
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Site PI · Recruiting · Phase 3
Stemline Therapeutics, Inc.
2024–2032
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2024–2030